Fortunately, patients with CMS due to Rapsyn mutation remarkably respond to anticholinesterase medication, such as pyridostigmine, and sometimes, addition with 3,4-DAP, ephedrine, or albuterol results in significant clinical improvement. The gene discussed is RAPSN; the disease is congenital myasthenic syndrome.